Author: admin

“Eczema Treatment Market”

(Albany, USA) DelveInsight’s “Eczema Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Eczema, historical and forecasted epidemiology as well as the Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Eczema market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Eczema market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Eczema treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Eczema market.

Request for a Free Sample Report @ Eczema Market Forecast

Some facts of the Eczema Market Report are:

• According to DelveInsight, Eczema market size is expected to grow at a decent CAGR by 2032.
• Leading Eczema companies working in the market are Sanofi S.A., Power Life Sciences Inc, Encore Dermatology Inc, AbbVie Inc., Kymab Limited, F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Stiefel, Basilea Pharmaceutica, GlaxoSmithKline, Anacor Pharmaceuticals Inc., Meda AB, Eli Lilly, GlaxoSmithKline plc, AstraZeneca plc, Pfizer, and others.
• Key Eczema Therapies expected to launch in the market are alitretinoin, KY1005, Dupilumab, Lebrikizumab, Topical corticosteroid, and others.
• In March 2025, Alphyn Biologics, announced results of Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical Zabalafin Hydrogel Versus Vehicle in the Treatment of Participants with Mild to Moderate Atopic Dermatitis (CLEAR-AD1)
• In March 2025, Pfizer announced results of a Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.
• In February 2025, Evommune, Inc. announced results of a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults with Atopic Dermatitis
• In February 2025, Almirall, S.A. announced results of a European, Multicenter, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Patients with Moderate-to-Severe Atopic Dermatitis
• In December 2024, Galderma today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.
• In September 2024, Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.1 Eczema inflammation under the skin can lead to symptoms seen and felt on the outside. EBGLYSS works by targeting eczema inflammation throughout the body that can lead to dry, itchy and irritated skin.
• In July 2024, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been specifically developed to be a treatment option for long-term disease control.
• In June 2023, Eli Lilly and Company announced a study to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to
• In March 2023, Sanofi and Kymab Limited announced an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis.

Eczema Overview

Eczema, also known as atopic dermatitis (AD), is a chronic inflammatory skin condition characterized by itchy, red, dry, and inflamed skin. It is a common immune-mediated disorder that affects both children and adults, with symptoms varying in severity. Eczema is driven by a combination of genetic, environmental, and immune system factors, leading to skin barrier dysfunction, increased transepidermal water loss (TEWL), and hypersensitivity to allergens and irritants.

Symptoms of eczema include intense pruritus (itching), erythema (redness), scaling, cracking, and oozing. Common triggers include allergens, irritants, stress, climate changes, and certain foods. Patients often experience flares and remissions, making long-term management essential.

Eczema Diagnosis is clinical, based on symptoms and history, but may involve patch testing, skin biopsies, and blood tests for elevated IgE levels. Eczema Treatment options include topical corticosteroids, calcineurin inhibitors, emollients, antihistamines, and biologics such as IL-4 and IL-13 inhibitors (dupilumab). In severe cases, systemic immunosuppressants, JAK inhibitors, and phototherapy may be required.

Emerging Eczema therapies, advanced biologics, and personalized medicine are transforming eczema treatment, offering better symptom control and long-term disease management. Proper skincare routines, moisturization, and trigger avoidance are key to preventing flares and improving quality of life.

Learn more about Eczema treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/eczema-market

Eczema Market

The Eczema market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Eczema market trends by analyzing the impact of current Eczema therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Eczema market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Eczema market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The eczema market is driven by the rising prevalence of atopic dermatitis (AD), increasing awareness of skin barrier dysfunction, and advancements in targeted therapies. The growing adoption of biologic treatments, such as IL-4 and IL-13 inhibitors (e.g., dupilumab), JAK inhibitors (e.g., upadacitinib, abrocitinib), and advanced topical therapies, has significantly improved disease management. Additionally, increased healthcare spending, improved diagnostic techniques, and patient education initiatives are fueling market growth. The demand for non-steroidal treatments, natural skincare products, and personalized medicine is also shaping the industry.

However, the market faces barriers, including high treatment costs, limited access to advanced therapies in developing regions, and safety concerns associated with long-term immunosuppressant use. The chronic and relapsing nature of eczema makes long-term management challenging, often leading to patient non-compliance and reliance on over-the-counter treatments. Additionally, stringent regulatory approvals, competition from generic and alternative therapies, and reimbursement limitations restrict market expansion. Despite these challenges, ongoing research in innovative biologics, microbiome-based therapies, and skin barrier repair treatments continues to drive advancements, improving patient outcomes and expanding therapeutic options in the eczema treatment market.

According to DelveInsight, the Eczema market in 7MM is expected to witness a major change in the study period 2019-2032.

Eczema Epidemiology

The Eczema epidemiology section provides insights into the historical and current Eczema patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Eczema market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Eczema Epidemiology @ Eczema Prevalence

Eczema Drugs Uptake

This section focuses on the uptake rate of the potential Eczema drugs recently launched in the Eczema market or expected to be launched in 2019-2032. The analysis covers the Eczema market uptake by drugs, patient uptake by therapies, and sales of each drug.

Eczema Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Eczema market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Eczema Pipeline Development Activities

The Eczema report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Eczema key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Eczema pipeline development activities @ Eczema Medication and Companies

Eczema Therapeutics Assessment

Major key companies are working proactively in the Eczema Therapeutics market to develop novel therapies which will drive the Eczema treatment markets in the upcoming years are Sanofi S.A., Power Life Sciences Inc, Encore Dermatology Inc, AbbVie Inc., Kymab Limited, F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Stiefel, Basilea Pharmaceutica, GlaxoSmithKline, Anacor Pharmaceuticals Inc., Meda AB, Eli Lilly, GlaxoSmithKline plc, AstraZeneca plc, Pfizer, and others.

Learn more about the emerging Eczema therapies & key companies @ Eczema Clinical Trials and Advancements

Eczema Report Key Insights

1. Eczema Patient Population

2. Eczema Market Size and Trends

3. Key Cross Competition in the Eczema Market

4. Eczema Market Dynamics (Key Drivers and Barriers)

5. Eczema Market Opportunities

6. Eczema Therapeutic Approaches

7. Eczema Pipeline Analysis

8. Eczema Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Eczema Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Eczema Competitive Intelligence Analysis

4. Eczema Market Overview at a Glance

5. Eczema Disease Background and Overview

6. Eczema Patient Journey

7. Eczema Epidemiology and Patient Population

8. Eczema Treatment Algorithm, Current Treatment, and Medical Practices

9. Eczema Unmet Needs

10. Key Endpoints of Eczema Treatment

11. Eczema Marketed Products

12. Eczema Emerging Therapies

13. Eczema Seven Major Market Analysis

14. Attribute Analysis

15. Eczema Market Outlook (7 major markets)

16. Eczema Access and Reimbursement Overview

17. KOL Views on the Eczema Market

18. Eczema Market Drivers

19. Eczema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eczema Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight

“Prurigo Nodularis Treatment Market”

(Albany, USA) DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Prurigo Nodularis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Prurigo Nodularis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Prurigo Nodularis market.

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast

Some of the key facts of the Prurigo Nodularis Market Report:

• The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, Incyte (Nasdaq:INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
• In February 2025, Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years of age and older with a body weight of at least 30kg, who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
• In August 2024, Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection to treat adults with prurigo nodularis. Nemluvio received Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024, highlighting its potential to significantly enhance treatment for serious conditions.
• In March 2024, Incyte revealed recently released late-breaking data from a Phase II study assessing povorcitinib in individuals diagnosed with prurigo nodularis.
• According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients.
• In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis.
• DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development.
• Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
• Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
• The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis
• The Prurigo Nodularis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics.

Prurigo Nodularis Overview

Prurigo Nodularis (PN) is a chronic inflammatory skin disorder characterized by the presence of multiple, intensely itchy, firm nodules that develop due to prolonged scratching and skin trauma. The exact cause of Prurigo Nodularis remains unclear, but it is associated with immune system dysregulation, chronic pruritus, nerve abnormalities, and underlying conditions such as atopic dermatitis, diabetes, chronic kidney disease, HIV, and psychiatric disorders.

Prurigo Nodularis Patients experience severe, persistent pruritus (itching), often leading to excoriated, hyperpigmented, or lichenified nodules that typically affect the arms, legs, and trunk. The itch-scratch cycle worsens the condition, making it difficult to treat. Prurigo Nodularis significantly impacts quality of life, causing sleep disturbances, anxiety, depression, and social embarrassment.

Prurigo Nodularis Diagnosis is clinical, based on the characteristic nodules and patient history, but may require skin biopsies, blood tests, or nerve function assessments to rule out underlying conditions. Treatment focuses on breaking the itch-scratch cycle using topical corticosteroids, calcineurin inhibitors, antihistamines, and emollients. In severe cases, biologic therapies (such as IL-31 inhibitors), immunosuppressants, gabapentinoids, and phototherapy may be needed. Recent advancements in targeted biologics and neuromodulators are improving outcomes, offering new hope for long-term disease control and symptom relief in Prurigo Nodularis patients.

Get a Free sample for the Prurigo Nodularis Market Report: https://www.delveinsight.com/report-store/prurigo-nodularis-market

Prurigo Nodularis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prurigo Nodularis Epidemiology Segmentation:

The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Prurigo Nodularis
• Prevalent Cases of Prurigo Nodularis by severity
• Gender-specific Prevalence of Prurigo Nodularis
• Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prurigo Nodularis Therapies and Key Companies

• Nalbuphine ER: Trevi Therapeutics
• Nemolizumab: Galderma
• Vixarelimab(KPL-716): Genentech
• Povorcitinib(INCB-54707): Incyte Corporation
• Ruxolitinib Cream: Incyte Corporation
• INCB054707: Incyte Corporation
• serlopitant: Vyne Therapeutics Inc.
• CC-10004: Celgene Corporation
• Pimecrolimus: Novartis
• Abrocitinib: Pfizer
• Dupilumab SAR231893: Regeneron Pharma

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market

Prurigo Nodularis Market Strengths

Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options. Vixarelimab’s dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

Prurigo Nodularis Market Opportunities

Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market. Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies.

Scope of the Prurigo Nodularis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
• Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
• Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies
• Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Prurigo Nodularis Unmet Needs, KOL’s views, Analyst’s views, Prurigo Nodularis Market Access and Reimbursement

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Prurigo Nodularis Market Report Introduction

2. Executive Summary for Prurigo Nodularis

3. SWOT analysis of Prurigo Nodularis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Prurigo Nodularis Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2020–2034)

14. Prurigo Nodularis Market Access and Reimbursement of Therapies

15. Prurigo Nodularis Market Drivers

16. Prurigo Nodularis Market Barriers

17. Prurigo Nodularis Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prurigo Nodularis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight

“Non-Cystic Fibrosis Bronchiectasis Pipeline”

(Albany, USA) “Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market.

The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

As per DelveInsight’s assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 16+ key companies continuously working towards developing 17+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Request for Sample Report @ Non-Cystic Fibrosis Bronchiectasis Pipeline Outlook

Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report:

• NCFB Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years.
• Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment.
• Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years.
• In February 2025, Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brensocatib for patients with non-cystic fibrosis bronchiectasis.
• In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting.
• In July 2024, Armata Pharmaceuticals stated that it had completed enrollment in its Tailwind Phase 2 clinical trial of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection.
• In May 2024, Insmed Incorporated reported encouraging topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate brensocatib’s effectiveness, safety, and tolerability in patients with non-cystic fibrosis bronchiectasis. The study accomplished its primary aim, with both brensocatib dose strengths showing statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) compared to placebo. The study also met several of its predetermined secondary goals with statistical significance.
• In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY.
• In December 2022, Haisco Pharmaceutical Group Co., Ltd. has commenced a trial titled “Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study.” This study aims to evaluate the effectiveness and safety of HSK31858 in individuals diagnosed with Non-cystic Fibrosis Bronchiectasis.
• In April 2022, The FDA awarded breakthrough therapy designation to colistimethate sodium powder intended for nebulization solution to alleviate pulmonary exacerbations in adults afflicted with Non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa. The basis for the FDA’s breakthrough therapy designation was supported by findings from the phase III PROMIS-I study, showcasing that CMS I-neb notably decreased annual rates of pulmonary exacerbations compared to a placebo within this patient population.

Non-Cystic Fibrosis Bronchiectasis Overview

Non-Cystic Fibrosis Bronchiectasis (NCFBE) is a chronic lung condition characterized by permanent dilation and damage of the bronchi, leading to impaired mucus clearance and recurrent infections. Unlike cystic fibrosis-related bronchiectasis, NCFBE is caused by underlying conditions such as chronic infections, autoimmune diseases, primary ciliary dyskinesia, allergic bronchopulmonary aspergillosis (ABPA), or immune deficiencies.

Patients with NCFBE experience persistent cough, excessive mucus production, recurrent respiratory infections, and shortness of breath, fatigue, and wheezing. The accumulation of mucus creates a breeding ground for bacteria, leading to frequent exacerbations and lung function decline. Common pathogens, including Pseudomonas aeruginosa and Haemophilus influenzae, contribute to disease progression and complications.

Non-Cystic Fibrosis Bronchiectasis Diagnosis involves high-resolution computed tomography (HRCT) scans, pulmonary function tests, sputum cultures, and blood tests to identify underlying causes. Non-Cystic Fibrosis Bronchiectasis Treatment focuses on airway clearance therapies, bronchodilators, inhaled antibiotics, corticosteroids, and mucolytics to reduce symptoms and prevent exacerbations. Pulmonary rehabilitation, vaccination, and lifestyle modifications also play a crucial role in disease management. While NCFBE is a chronic and progressive condition, advancements in targeted therapies, biologics, and precision medicine are improving patient outcomes, reducing exacerbations, and enhancing quality of life.

Get a Free Sample PDF Report to know more about the phases of drugs in development, ROA and MOA , click here @ Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment

Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:

• NP339: NovaBiotics Ltd
• Research Programme:NCFB: Synspira Therapeutics
• Research programme: mucolytic agents: Parion Sciences
• CHF 6333: Chiesi Farmaceutic
• CSL787: CSL Behring
• HSK31858: Haisco Pharmaceutical
• S-1226: SolAeroMed Inc.
• Benralizumab: AstraZeneca
• Colistimethate sodium: Zambon SpA
• BI 1291583: Boehringer Ingelheim
• AP-PA02: Armata Pharmaceuticals
• ARINA-1: Renovion

Non-Cystic Fibrosis Bronchiectasis Route of Administration

Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Non-Cystic Fibrosis Bronchiectasis Molecule Type

Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment

• Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type
• Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type
• Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration
• Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration
• Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type
• Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type

DelveInsight’s Non-Cystic Fibrosis Bronchiectasis Report covers around 17+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies @ Non-Cystic Fibrosis Bronchiectasis Treatment Market

Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:

Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are – Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others.

Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis:

The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
• Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies – Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Advancements

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers

Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market.

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers

However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth.

Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight

• Coverage: Global
• Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers

Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials – Non-Cystic Fibrosis Bronchiectasis Companies and Drugs

Table of Contents

1. Non-Cystic Fibrosis Bronchiectasis Report Introduction

2. Non-Cystic Fibrosis Bronchiectasis Executive Summary

3. Non-Cystic Fibrosis Bronchiectasis Overview

4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment

5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics

6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III)

7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)

8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)

9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products

10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment

11. Non-Cystic Fibrosis Bronchiectasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Cystic Fibrosis Bronchiectasis Key Companies

14. Non-Cystic Fibrosis Bronchiectasis Key Products

15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs

16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers

17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion

18. Non-Cystic Fibrosis Bronchiectasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

“Common Warts Treatment Market”

(Albany, USA) DelveInsight’s “Common Warts Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Common Warts market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Common Warts market size from 2019 to 2032, segmented by seven major markets. The report also covers current Common Warts treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Common Warts market.

To Know in detail about the Common Warts market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Common Warts Market Forecast

Some of the key facts of the Common Warts Market Report:

• The Common Warts market size was valued approximately USD 725 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Key Common Warts Companies: KinoPharma Inc., Veradermics, Inc., Labo’Life, Merck Sharp & Dohme LLC, Shanghai Zerun Biotechnology, X4 Pharmaceuticals, Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
• Key Common Warts Therapies: KNP2002, VDMN-21, 2LVERU® or 2LVERU® JUNIOR, V503, Zerun HPV-9, Mavorixafor, CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
• In February 2025, Nielsen BioSciences, Inc. announced results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults
• In November 2024, Veradermics, Inc announced results of Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
• In October 2024, Labo’Life has announced a Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.
• According to DelveInsight’s evaluation, in 2022, the total number of diagnosed prevalent cases of common warts in the 7MM was estimated to be around 14,964,357 cases.
• In the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of common warts in 2022, totalling approximately 2,824,294 cases. This represented nearly 19% of the total diagnosed prevalent cases in the 7MM.
• In 2022, the EU4 countries and the UK collectively had around 10,779,827 diagnosed prevalent cases of common warts.
• This constituted the majority of cases, covering an estimated 72% of the total cases in the 7MM.
• In the EU4 countries and the UK, Germany had the highest total number of diagnosed prevalent cases of common warts in 2022, totaling approximately 2,628,032 cases. This was followed by France and the UK, with approximately 2,247,383 and 2,184,658 cases respectively.
• The Common Warts epidemiology based on gender analyzed that the diagnosed prevalent cases were observed to be same for male and female in the 7MM
• The Common Warts market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Common Warts pipeline products will significantly revolutionize the Common Warts market dynamics.

Common Warts Overview

Common warts, also known as verruca vulgaris, are benign skin growths caused by the human papillomavirus (HPV), primarily types 2, 4, 27, and 57. They develop when the virus infects the top layer of the skin, often through small cuts or abrasions. Common warts are highly contagious, spreading through direct skin contact or contaminated surfaces.

These warts appear as rough, raised, skin-colored or grayish lesions with a cauliflower-like texture. They are most commonly found on the hands, fingers, elbows, and knees, though they can occur anywhere on the body. While generally painless, they may cause discomfort or irritation, especially in high-friction areas.

Diagnosis is typically clinical, based on their characteristic appearance. In uncertain cases, a skin biopsy may be performed. Most common warts resolve spontaneously over time, but treatment may be necessary for persistent or bothersome lesions. Options include topical salicylic acid, cryotherapy (freezing with liquid nitrogen), laser therapy, electrosurgery, and immunotherapy. Preventive measures such as good hygiene, avoiding direct contact with warts, and strengthening the immune system can reduce the risk of infection. Ongoing research into antiviral therapies and immune-modulating treatments is expanding future treatment possibilities for common warts.

Get a Free sample for the Common Warts Market Report: https://www.delveinsight.com/sample-request/common-warts-market

Common Warts Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Common Warts Epidemiology Segmentation:

The Common Warts market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Common Warts
• Prevalent Cases of Common Warts by severity
• Gender-specific Prevalence of Common Warts
• Diagnosed Cases of Episodic and Chronic Common Warts

Download the report to understand which factors are driving Common Warts epidemiology trends @ Common Warts Epidemiology Forecast

Common Warts Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched during the study period. The analysis covers Common Warts market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Common Warts Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Common Warts Therapies and Key Companies

• KNP2002: KinoPharma Inc.
• 2LVERU® or 2LVERU® JUNIOR: Labo’Life
• V503: Merck Sharp & Dohme LLC
• Zerun HPV-9: Shanghai Zerun Biotechnology
• Mavorixafor: X4 Pharmaceuticals
• CANDIN: Nielsen BioSciences/Maruho
• VP-102: Verrica Pharmaceutical
• FIT039: Kino Pharma/ Iwaki Pharmaceutical
• A-101: Aclaris Therapeutics, Inc.
• KNP2002: KinoPharma Inc.
• 10% EISO: ViroXis Corporation
• CLS006: Maruho Co., Ltd.
• VDMN-21: Veradermics, Inc.
• Resiquimod: Graceway Pharmaceuticals, LLC
• Imiquimod: MEDA Pharma
• Picato: LEO Pharma

To know more about latest happenings in Common Warts, visit @ Common Warts Medication and Treatment Market

Common Warts Market Strengths

The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes. An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years.

Common Warts Market Opportunities

Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously.

Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness

Scope of the Common Warts Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Common Warts Companies: KinoPharma Inc., Veradermics, Inc., Labo’Life, Merck Sharp & Dohme LLC, Shanghai Zerun Biotechnology, X4 Pharmaceuticals, Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
• Key Common Warts Therapies: KNP2002, VDMN-21, 2LVERU® or 2LVERU® JUNIOR, V503, Zerun HPV-9, Mavorixafor, CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
• Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies
• Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Common Warts Unmet Needs, KOL’s views, Analyst’s views, Common Warts Market Access and Reimbursement

To know more about Common Warts companies working in the treatment market, visit @ Common Warts Clinical Trials and Therapeutic Assessment­­­

Table of Contents

1. Common Warts Market Report Introduction

2. Executive Summary for Common Warts

3. SWOT analysis of Common Warts

4. Common Warts Patient Share (%) Overview at a Glance

5. Common Warts Market Overview at a Glance

6. Common Warts Disease Background and Overview

7. Common Warts Epidemiology and Patient Population

8. Country-Specific Patient Population of Common Warts

9. Common Warts Current Treatment and Medical Practices

10. Common Warts Unmet Needs

11. Common Warts Emerging Therapies

12. Common Warts Market Outlook

13. Country-Wise Common Warts Market Analysis (2020–2034)

14. Common Warts Market Access and Reimbursement of Therapies

15. Common Warts Market Drivers

16. Common Warts Market Barriers

17. Common Warts Appendix

18. Common Warts Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight

“Chronic Hand Eczema Medication Market”

(Albany, USA) DelveInsight’s “Chronic Hand Eczema Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Hand Eczema, historical and forecasted epidemiology as well as the Chronic Hand Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Hand Eczema pipeline products will significantly revolutionize the Chronic Hand Eczema market dynamics.

The Chronic Hand Eczema market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Hand Eczema market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Chronic Hand Eczema treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Hand Eczema market.

To Know in detail about the Chronic Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Hand Eczema Market Forecast

Some of the key facts of the Chronic Hand Eczema Market Report:

• The Chronic Hand Eczema market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In September 2024, LEO Pharma Inc. garnered attention with two significant announcements. Firstly, the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%), designed for adults experiencing moderate to severe Chronic Hand Eczema (CHE). This development is particularly important for patients who have not had favorable responses to topical corticosteroids or for those for whom such treatments are inappropriate.
• In September 2024, LEO Pharma A/S announced that the European Commission (EC) has granted marketing authorization for Anzupgo® (delgocitinib) cream. This approval provides a new treatment option for adult patients with moderate to severe Chronic Hand Eczema (CHE) in Europe, particularly where conventional corticosteroid therapies have been ineffective. These two announcements highlight LEO Pharma’s continued leadership in medical dermatology and represent a significant advancement in enhancing care for individuals suffering from chronic hand eczema.
• In 2023, the market size for chronic hand eczema in the US was approximately USD 431 million.
• In 2023, Germany had the largest market size among the EU4 and the UK, at approximately USD 71 million, followed by France at nearly USD 46 million and the UK at around USD 45 million.
• In 2023, Japan’s chronic hand eczema market size was approximately USD 93 million of the total market share.
• According to DelveInsight’s analysis, the total prevalent cases of chronic hand eczema in the 7MM were about 4 million in 2023, with nearly 2 million of those cases occurring in the US.
• Within the EU4 and the UK, Germany had the highest number of prevalent chronic hand eczema cases, with nearly 493,000 cases, followed by France and the UK with approximately 321,000 and 317,000 cases, respectively.
• In the UK in 2023, there were approximately 52,000 cases of chronic hand eczema in the 20-29 age group, 98,000 cases in the 30-49 age group, 29,000 cases in the 50-69 age group, and 26,000 cases in the 70 and above age group.
• In 2023, Japan accounted for nearly 15% of all chronic hand eczema cases worldwide. Among the various subtypes, irritant contact eczema had the highest prevalence at around 27%, while fingertip eczema was the least common, making up approximately 4% of the cases.
• Key Chronic Hand Eczema Companies: Basilea Pharmaceutica/ Stiefel Laboratories, LEO Pharma, Asana Biosciences and Incyte Corporation, and others
• Key Chronic Hand Eczema Therapies: TOCTINO (alitretinoin), Delgocitinib, Ruxolitinib, ASN002, and others
• The Chronic Hand Eczema epidemiology based on gender analyzed that Chronic Hand Eczema is more common in males, than females

Chronic Hand Eczema Overview

Chronic Hand Eczema (CHE) is a persistent inflammatory skin condition affecting the hands, characterized by redness, scaling, itching, cracking, blistering, and pain. It is a common condition, particularly among individuals exposed to irritants and allergens, such as healthcare workers, cleaners, hairdressers, and construction workers. Genetic predisposition, impaired skin barrier function, immune system dysregulation, and environmental triggers contribute to its development.

The condition is classified into different subtypes, including irritant contact dermatitis, allergic contact dermatitis, atopic hand eczema, and hyperkeratotic eczema. Symptoms often worsen with frequent handwashing, chemical exposure, temperature changes, and mechanical friction. Chronic Hand Eczema can severely impact quality of life, leading to functional impairment, sleep disturbances, and psychological distress.

Chronic Hand Eczema Diagnosis is typically clinical, based on symptoms and history, but may involve patch testing, skin biopsies, or IgE level assessments to identify underlying triggers. Treatment focuses on avoiding irritants, using emollients, topical corticosteroids, calcineurin inhibitors, and barrier creams. In severe cases, systemic immunosuppressants, biologics (such as IL-4/IL-13 inhibitors), JAK inhibitors, and phototherapy may be required. Early intervention, long-term skin care, and emerging targeted therapies are key to improving outcomes and preventing relapses in patients with Chronic Hand Eczema.

Get a Free sample for the Chronic Hand Eczema Market Report: https://www.delveinsight.com/report-store/chronic-hand-eczema-market

Chronic Hand Eczema Epidemiology Segmentation:

The Chronic Hand Eczema market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Chronic Hand Eczema
• Prevalent Cases of Chronic Hand Eczema by severity
• Gender-specific Prevalence of Chronic Hand Eczema
• Diagnosed Cases of Episodic and Chronic Chronic Hand Eczema

Download the report to understand which factors are driving Chronic Hand Eczema epidemiology trends @ Chronic Hand Eczema Epidemiological Insights

Chronic Hand Eczema Market

The dynamics of the Chronic Hand Eczema market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Chronic Hand Eczema Therapies and Key Companies

• TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories
• Delgocitinib: LEO Pharma/Japan Tobacco
• ARQ-252: Arcutis Biotherapeutics
• ASN002: Asana BioScience
• Ruxolitinib: Incyte Corporation

To know more about Chronic Hand Eczema treatment, visit @ Chronic Hand Eczema Medications and Companies

Chronic Hand Eczema Market Drivers

• Government Initiatives
• Growth in Research and Development
• Increase in the number of patients

Chronic Hand Eczema Market Barriers

• Lack of Approved Chronic Hand Eczema therapies
• Lack of Clinical Trial studies

Scope of the Chronic Hand Eczema Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Hand Eczema Companies: Basilea Pharmaceutica, Stiefel Laboratories, LEO Pharma, Incyte Corporation, Asana BioSciences, and others
• Key Chronic Hand Eczema Therapies: TOCTINO (alitretinoin), Delgocitinib, Ruxolitinib, ASN002, and others
• Chronic Hand Eczema Therapeutic Assessment: Chronic Hand Eczema current marketed and Chronic Hand Eczema emerging therapies
• Chronic Hand Eczema Market Dynamics: Chronic Hand Eczema market drivers and Chronic Hand Eczema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Chronic Hand Eczema Market Access and Reimbursement

Discover more about therapies set to grab major Chronic Hand Eczema market share @ Chronic Hand Eczema Clinical Trials and Treatment Landscape

Table of Contents

1. Chronic Hand Eczema Market Report Introduction

2. Executive Summary for Chronic Hand Eczema

3. SWOT analysis of Chronic Hand Eczema

4. Chronic Hand Eczema Patient Share (%) Overview at a Glance

5. Chronic Hand Eczema Market Overview at a Glance

6. Chronic Hand Eczema Disease Background and Overview

7. Chronic Hand Eczema Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Hand Eczema

9. Chronic Hand Eczema Current Treatment and Medical Practices

10. Chronic Hand Eczema Unmet Needs

11. Chronic Hand Eczema Emerging Therapies

12. Chronic Hand Eczema Market Outlook

13. Country-Wise Chronic Hand Eczema Market Analysis (2020–2034)

14. Chronic Hand Eczema Market Access and Reimbursement of Therapies

15. Chronic Hand Eczema Market Drivers

16. Chronic Hand Eczema Market Barriers

17. Chronic Hand Eczema Appendix

18. Chronic Hand Eczema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Hand Eczema Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight